Evidence of altered dopaminergic modulation of prolactin and thyrotropin secretion in patients with polycystic ovary syndrome.
In order to evaluate the functional activity of the tubero-infundibular dopaminergic system in polycystic ovary syndrome (PCOS), we analysed the prolactin (PRL) and thyrotropin (TSH) responses to the dopamine antagonist sulpiride. We studied 8 euthyroid women affected by PCOS and 7 normal women. The mean baseline PRL values were normal in both groups. After sulpiride administration the incremental area under the PRL profile in PCOS was significantly lower than in normal subjects (p less than 0.01). The mean basal plasma TSH levels were significantly higher in the PCOS than in the control group (p less than 0.01). After sulpiride administration the incremental area under the TSH profile was significantly lower in PCOS patients than in normal women (p less than 0.01). The higher basal plasma levels of TSH, the blunted response of PRL and the lack of response of TSH to sulpiride in PCOS suggest a relative decrease of the dopaminergic activity in PCOS patients.
Velardo
A
A
Department of Endocrinology, University of Modena, Italy.
Pantaleoni
M
M
Zironi
C
C
Zizzo
G
G
Marrama
P
P
D000293:Adolescent; D000328:Adult; D004298:Dopamine / Q000502:physiology*; D018492:Dopamine Antagonists; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007700:Kinetics; D007986:Luteinizing Hormone / Q000097:blood; D011085:Polycystic Ovary Syndrome / Q000503:physiopathology*; D011388:Prolactin / Q000378:metabolism*; D013469:Sulpiride; D013972:Thyrotropin / Q000378:metabolism*
D018492:Dopamine Antagonists; D013469:Sulpiride; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin; D004298:Dopamine